{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:51:54Z","timestamp":1793055114211,"version":"4.5.0"},"reference-count":154,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) and atrial fibrillation (AF) are two highly prevalent conditions that share overlapping cardiometabolic risk factors, including obesity, type 2 diabetes, hypertension, and dyslipidemia. Growing evidence suggests that these two disease entities are pathophysiologically linked through systemic inflammation, oxidative stress, and structural remodeling. Population-based studies and meta-analyses report an association between steatotic liver disease and both incident and recurrent AF. While several analyses observe persistence of this association after adjustment for cardiometabolic risk factors, residual confounding and limitations of observational designs preclude firm causal inference. Conversely, heart rhythm disturbances may exacerbate hepatic fibrosis and dysfunction. Lifestyle interventions\u2014particularly sustained weight loss\u2014have demonstrated significant benefits in both conditions. Emerging pharmacological options, including incretin mimetics, flozins, statins, and thiazolidinediones, show promise in addressing the liver\u2013heart axis, while appropriate anticoagulation remains essential in AF management. This review summarizes current epidemiological data, mechanistic insights, diagnostic approaches, and therapeutic strategies related to the coexistence of MASLD and AF. Emphasis is placed on shared pathogenic pathways, non-invasive diagnostic tools, and integrated management options.<\/jats:p>","DOI":"10.3390\/life15111713","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:19:29Z","timestamp":1762348769000},"page":"1713","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Crosstalk Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Atrial Fibrillation: Shared Mechanism, Diagnostic Integration, and Management Implications"],"prefix":"10.3390","volume":"15","author":[{"given":"Agata","family":"Morawska","sequence":"first","affiliation":[{"name":"Students\u2019 Research Club, Department of Clinical Pharmacology, Medical University of Lodz, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5055-1738","authenticated-orcid":false,"given":"Rafa\u0142","family":"Frankowski","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Lodz, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3529-1989","authenticated-orcid":false,"given":"Miko\u0142aj","family":"Grabarczyk","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Lodz, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0609-9657","authenticated-orcid":false,"given":"Marcin","family":"Kosmalski","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Lodz, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-5659","authenticated-orcid":false,"given":"Monika","family":"R\u00f3\u017cycka-Kosmalska","sequence":"additional","affiliation":[{"name":"Department of Electrocardiology, Medical University of Lodz, 92-213 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review","volume":"32","author":"Chan","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"EASL, EASD, and EASO (2024). EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Obes. Facts, 17, 374\u2013444.","DOI":"10.1159\/000539371"},{"key":"ref_3","first-page":"691","article-title":"MASLD: A systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: A systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Frankowski, R., Kobierecki, M., Wittczak, A., R\u00f3\u017cycka-Kosmalska, M., Pietras, T., Sipowicz, K., and Kosmalski, M. (2023). Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119677"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Syed-Abdul, M.M. (2023). Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD). Metabolites, 14.","DOI":"10.3390\/metabo14010012"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Shang","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2023.11.005","article-title":"Natural history of metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Lekakis","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","article-title":"Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease","volume":"73","author":"Lee","year":"2024","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"106147","DOI":"10.4330\/wjc.v17.i6.106147","article-title":"Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis","volume":"17","author":"Bharaj","year":"2025","journal-title":"World J. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2023.11.012","article-title":"Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Haldrup","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/HEP.0000000000000925","article-title":"MASLD\/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up","volume":"81","author":"Kwak","year":"2025","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.CIR.0000140263.20897.42","article-title":"Lifetime Risk for Development of Atrial Fibrillation","volume":"110","author":"Wang","year":"2004","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation","volume":"83","author":"Joglar","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3349\/ymj.2020.61.10.860","article-title":"Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease","volume":"61","author":"Kang","year":"2020","journal-title":"Yonsei Med. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101676","DOI":"10.1016\/j.ijcha.2025.101676","article-title":"Metabolic dysfunction-associated steatotic liver disease and increased risk of atrial fibrillation in the elderly: A longitudinal cohort study","volume":"58","author":"Tang","year":"2025","journal-title":"IJC Heart Vasc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12933-025-02795-5","article-title":"Impact of steatotic liver diseases on diabetes mellitus risk in patients with atrial fibrillation: A nationwide population study","volume":"24","author":"Ryu","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41569-022-00820-8","article-title":"Epidemiology and modifiable risk factors for atrial fibrillation","volume":"20","author":"Elliott","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.mayocp.2019.08.027","article-title":"Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Atrial Fibrillation","volume":"95","author":"Pastori","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1111\/liv.16016","article-title":"The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes","volume":"44","author":"Riley","year":"2024","journal-title":"Liver Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12933-023-02070-5","article-title":"Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: A nationwide histology cohort study","volume":"22","author":"Simon","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s13679-019-00345-1","article-title":"Nonalcoholic Fatty Liver Disease and Obesity Treatment","volume":"8","author":"Brunner","year":"2019","journal-title":"Curr. Obes. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e042003","DOI":"10.1161\/JAHA.125.042003","article-title":"Metabolic Dysfunction\u2013Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population-Based Study","volume":"14","author":"Kim","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Cho, S.H., Kim, G., Lee, K., Oh, R., Kim, J.Y., Jang, M., Lee, Y.-B., Jin, S.-M., Hur, K.Y., and Han, K. (2025). Impact of steatotic liver disease categories on atrial fibrillation in type 2 diabetes: A nationwide study. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-94783-8"},{"key":"ref_29","first-page":"544","article-title":"Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: Just a coincidence?","volume":"34","author":"Targher","year":"2011","journal-title":"J. Endocrinol. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/10815589231164777","article-title":"Association between nonalcoholic fatty liver disease and atrial fibrillation and other clinical outcomes: A meta-analysis","volume":"71","author":"Jaiswal","year":"2023","journal-title":"J. Investig. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e16218","DOI":"10.1111\/liv.16218","article-title":"MASLD Is Associated With an Increased Long-Term Risk of Atrial Fibrillation: An Updated Systematic Review and Meta-Analysis","volume":"45","author":"Mantovani","year":"2025","journal-title":"Liver Int."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Wang, Y., Chen, Z., Wei, B., Zhang, R., Zhang, X., and Xu, W. (2025). Metabolic dysfunction associated steatotic liver disease is associated with atrial fibrillation recurrence following cryoballoon ablation. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-90667-z"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"102292","DOI":"10.1016\/j.eclinm.2023.102292","article-title":"Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: A nationwide cohort study","volume":"65","author":"Moon","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","article-title":"Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease","volume":"15","author":"Anstee","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.jacc.2015.10.047","article-title":"Obesity, Exercise, Obstructive Sleep Apnea, and Modifiable Atherosclerotic Cardiovascular Disease Risk Factors in Atrial Fibrillation","volume":"66","author":"Miller","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Knezovi\u0107, E., Hefer, M., Bla\u017eanovi\u0107, S., Petrovi\u0107, A., Tomi\u010di\u0107, V., Srb, N., Kirner, D., Smoli\u0107, R., and Smoli\u0107, M. (2025). Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom. Curr. Issues Mol. Biol., 47.","DOI":"10.3390\/cimb47030154"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Cheung, J., Cheung, B.M.-Y., Yiu, K.-H., Tse, H.-F., and Chan, Y.-H. (2025). Role of metabolic dysfunction-associated fatty liver disease in atrial fibrillation and heart failure: Molecular and clinical aspects. Front. Cardiovasc. Med., 12.","DOI":"10.3389\/fcvm.2025.1573841"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Ionescu, V.A., Gheorghe, G., Bacalbasa, N., and Diaconu, C.C. (2025). Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk. Biomolecules, 15.","DOI":"10.3390\/biom15020163"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/liv.14044","article-title":"Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis","volume":"39","author":"Mantovani","year":"2019","journal-title":"Liver Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00204-024-03889-x","article-title":"Metabolic dysfunction-associated steatotic liver disease-induced changes in the antioxidant system: A review","volume":"99","year":"2025","journal-title":"Arch. Toxicol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/CM9.0000000000003629","article-title":"MASLD development: From molecular pathogenesis toward therapeutic strategies","volume":"138","author":"Yang","year":"2025","journal-title":"Chin. Med. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12944-024-02382-9","article-title":"Ergothioneine ameliorates metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) by enhancing autophagy, inhibiting oxidative damage and inflammation","volume":"23","author":"Lv","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Qiu, X., Shen, S., Jiang, N., Feng, Y., Yang, G., and Lu, D. (2025). Associations between systemic inflammatory biomarkers and metabolic dysfunction associated steatotic liver disease: A cross-sectional study of NHANES 2017\u20132020. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-03625-4"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12933-024-02408-7","article-title":"Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups","volume":"23","author":"Cho","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.yjmcc.2024.09.011","article-title":"Oxidative stress and atrial fibrillation","volume":"196","author":"Pfenniger","year":"2024","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41392-023-01687-y","article-title":"The role of inflammasomes in human diseases and their potential as therapeutic targets","volume":"9","author":"Yao","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Xing, Y., Yan, L., Li, X., Xu, Z., Wu, X., Gao, H., Chen, Y., Ma, X., Liu, J., and Zhang, J. (2023). The relationship between atrial fibrillation and NLRP3 inflammasome: A gut microbiota perspective. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1273524"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., and Singh, B.K. (2024). Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1433857"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100832","DOI":"10.1016\/j.diff.2024.100832","article-title":"Deciphering endocrine function of adipose tissue and its significant influences in obesity-related diseases caused by its dysfunction","volume":"141","author":"Duan","year":"2025","journal-title":"Differentiation"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Hemat Jouy, S., Mohan, S., Scichilone, G., Mostafa, A., and Mahmoud, A.M. (2024). Adipokines in the Crosstalk between Adipose Tissues and Other Organs: Implications in Cardiometabolic Diseases. Biomedicines, 12.","DOI":"10.3390\/biomedicines12092129"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Francisco, V., Sanz, M.J., Real, J.T., Marques, P., Capuozzo, M., Ait Eldjoudi, D., and Gualillo, O. (2022). Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?. Biology, 11.","DOI":"10.3390\/biology11081237"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Xie, L., Wang, H., Hu, J., Liu, Z., and Hu, F. (2024). The role of novel adipokines and adipose-derived extracellular vesicles (ADEVs): Connections and interactions in liver diseases. Biochem. Pharmacol., 222.","DOI":"10.1016\/j.bcp.2024.116104"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/HEP.0000000000000735","article-title":"Metabolic dysfunction-associated steatotic liver disease and the heart","volume":"82","author":"Driessen","year":"2025","journal-title":"Hepatology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13098-025-01796-4","article-title":"CARDIAL-MS (CArdio-Renal-DIAbetes-Liver-Metabolic Syndrome): A new proposition for an integrated multisystem metabolic disease","volume":"17","author":"Sposito","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2395565","DOI":"10.1080\/21623945.2024.2395565","article-title":"The change of epicardial adipose tissue characteristics and vulnerability for atrial fibrillation upon drastic weight loss","volume":"13","author":"Meulendijks","year":"2024","journal-title":"Adipocyte"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"110170","DOI":"10.1016\/j.clinimag.2024.110170","article-title":"Epicardial adipose tissue volume assessed by cardiac CT as a predictor of atrial fibrillation recurrence following catheter ablation","volume":"110","author":"Teixeira","year":"2024","journal-title":"Clin. Imaging"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"H129","DOI":"10.1152\/ajpheart.00565.2021","article-title":"Epicardial adipose tissue as a mediator of cardiac arrhythmias","volume":"322","author":"Patel","year":"2022","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"36598","DOI":"10.31083\/RCM36598","article-title":"Recent Advances in Inflammation-Associated Epicardial Adipose Tissue for Atrial Fibrillation Patients","volume":"26","author":"Li","year":"2025","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s44324-025-00063-4","article-title":"ECM formation and degradation during fibrosis, repair, and regeneration","volume":"3","author":"Leeming","year":"2025","journal-title":"npj Metab. Health Dis."},{"key":"ref_60","first-page":"e0374","article-title":"The role of sinusoidal endothelial cells and TIMP1 in the regulation of fibrosis in a novel human liver 3D NASH model","volume":"8","author":"Julien","year":"2024","journal-title":"Hepatol. Commun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"goae024","DOI":"10.1093\/gastro\/goae024","article-title":"Noninvasive tests for liver fibrosis in 2024: Are there different scales for different diseases?","volume":"12","author":"Lai","year":"2023","journal-title":"Gastroenterol. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4254\/wjh.v15.i2.201","article-title":"Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis","volume":"15","author":"Kram","year":"2023","journal-title":"World J. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Karakasis, P., Theofilis, P., Vlachakis, P.K., Korantzopoulos, P., Patoulias, D., Antoniadis, A.P., and Fragakis, N. (2024). Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26010209"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"101171","DOI":"10.1016\/j.jhepr.2024.101171","article-title":"Inflammation in liver fibrosis and atrial fibrillation: A prospective population-based proteomic study","volume":"6","author":"Boeckmans","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Zhang, S., Liang, H., Liu, J., Huang, Z., Shi, X., and Zhu, Y. (2025). The association between inflammatory, metabolic, and hepatic fibrosis-related biomarkers and atrial fibrillation in older patients with metabolic dysfunction-associated steatotic liver disease. BMC Geriatr., 25.","DOI":"10.1186\/s12877-025-06120-3"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41588-022-01199-5","article-title":"Multiomics study of nonalcoholic fatty liver disease","volume":"54","author":"Sveinbjornsson","year":"2022","journal-title":"Nat. Genet."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/apt.17292","article-title":"Review article: The role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD","volume":"57","author":"Amangurbanova","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MOG.0000000000000927","article-title":"Advances in the genetics of nonalcoholic fatty liver disease","volume":"39","author":"Ajmera","year":"2023","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"lnae030","DOI":"10.1093\/lifemedi\/lnae030","article-title":"Research on the function of epigenetic regulation in the inflammation of non-alcoholic fatty liver disease","volume":"3","author":"Sun","year":"2024","journal-title":"Life Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"156724","DOI":"10.1016\/j.cyto.2024.156724","article-title":"Inflammation-related miRNAs in obesity, CVD, and NAFLD","volume":"182","author":"Aghaei","year":"2024","journal-title":"Cytokine"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamacardio.2024.1528","article-title":"Rare and Common Genetic Variation Underlying Atrial Fibrillation Risk","volume":"9","author":"Vad","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Cheng, B., Su, X., He, J., Gu, Y., Chen, M., Wei, Y., Yi, Y., Chen, P., Lin, X., and Li, T. (2025). A Mendelian randomization study reveals a causal association between NASH and the risk of atrial fibrillation. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1390259"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s11357-024-01435-2","article-title":"Associations between MASLD, atrial fibrillation, cardiovascular events, mortality and aspirin use in older adults","volume":"47","author":"Roberts","year":"2024","journal-title":"GeroScience"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/RLI.0000000000000173","article-title":"Fifty Years of Technological Innovation","volume":"50","author":"Attenberger","year":"2015","journal-title":"Investig. Radiol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Kosmalski, M., and Mokros, \u0141. (2025). Non-Alcoholic Fatty Liver Disease in Everyday Clinical Practice: From Diagnosis to Therapy. Life, 15.","DOI":"10.3390\/life15030363"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Dawod, S., and Brown, K. (2024). Non-invasive testing in metabolic dysfunction-associated steatotic liver disease. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1499013"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Long, L., Wu, Y., Tang, H., Xiao, Y., Wang, M., Shen, L., Shi, Y., Feng, S., Li, C., and Lin, J. (2025). Development and validation of a scoring system to predict MASLD patients with significant hepatic fibrosis. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-91013-z"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s41043-024-00709-x","article-title":"Association of inflammation and nutrition-based indicators with chronic obstructive pulmonary disease and mortality","volume":"43","author":"Cao","year":"2024","journal-title":"J. Health Popul. Nutr."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7325","DOI":"10.2147\/JIR.S479253","article-title":"Analysis of the Clinical Predictive Value of the Novel Inflammatory Indices SII, SIRI, MHR and NHR in Patients with Acute Myocardial Infarction and Their Extent of Coronary Artery Disease","volume":"17","author":"Sun","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/ehf2.14336","article-title":"Comparison of liver fibrosis scores for predicting mortality and morbidity in heart failure with preserved ejection fraction","volume":"10","author":"Cao","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00392-023-02330-0","article-title":"Liver fibrosis and outcomes of atrial fibrillation: The FIB-4 index","volume":"113","year":"2024","journal-title":"Clin. Res. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s44355-025-00021-3","article-title":"Scores to predict steatotic liver disease\u2014Correlates and outcomes in older adults","volume":"2","author":"Commins","year":"2025","journal-title":"npj Gut Liver"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"102580","DOI":"10.1016\/j.cpcardiol.2024.102580","article-title":"Electrocardiographic abnormalities in patients with metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis","volume":"49","author":"Dimala","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Awashra, A., Nouri, A., Hamdan, A., Said, H., Rajab, I., Hussein, A., and Abu Rmilah, A. (2025). Metabolic Dysfunction-Associated Steatotic Liver Disease as a Cardiovascular Risk Factor: Focus on Atrial Fibrillation. Cardiol. Rev.","DOI":"10.1097\/CRD.0000000000000932"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","article-title":"Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease","volume":"179","author":"Koutoukidis","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2015.03.002","article-title":"Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort","volume":"65","author":"Pathak","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_87","first-page":"1","article-title":"Nonalcoholic fatty liver disease and atrial fibrillation: Possible pathophysiological links and therapeutic interventions","volume":"33","author":"Haghbin","year":"2020","journal-title":"Ann. Gastroenterol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1007\/s11695-019-03926-0","article-title":"Effect of Bariatric Surgery on Serum Inflammatory Factors of Obese Patients: A Systematic Review and Meta-Analysis","volume":"29","author":"Askarpour","year":"2019","journal-title":"Obes. Surg."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2022.04.002","article-title":"Breakthroughs in therapies for NASH and remaining challenges","volume":"76","author":"Ratziu","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","volume":"79","author":"Tacke","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","article-title":"Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver","volume":"79","author":"Newsome","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., and Sasso, F.C. (2023). GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021703"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"100917","DOI":"10.1016\/j.jpha.2023.12.007","article-title":"GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation","volume":"14","author":"Zhong","year":"2024","journal-title":"J. Pharm. Anal."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e14292","DOI":"10.1111\/eci.14292","article-title":"Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis","volume":"54","author":"Saglietto","year":"2024","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1007\/s12325-024-02959-x","article-title":"Effects of Glucagon-Like Peptide 1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Meta-analysis","volume":"41","author":"Karakasis","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1007\/s11606-023-08589-3","article-title":"Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: A real-world study","volume":"39","author":"Xu","year":"2024","journal-title":"J. Gen. Intern. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta-analysis: Pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis","volume":"35","author":"Boettcher","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Zhang, X., Korantzopoulos, P., Letsas, K.P., Tse, G., Gong, M., Meng, L., Li, G., and Liu, T. (2017). Thiazolidinedione use and atrial fibrillation in diabetic patients: A meta-analysis. BMC Cardiovasc. Disord., 17.","DOI":"10.1186\/s12872-017-0531-4"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/europace\/eur131","article-title":"Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus","volume":"13","author":"Gu","year":"2011","journal-title":"Europace"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"5861","DOI":"10.2174\/0109298673308673240527092317","article-title":"Pioglitazone Alleviates \u03b21-adrenergic Receptor Antibody-induced Atrial Fibrillation Susceptivity via Mitigation of PPAR-\u03b3-mediated Metabolic Inflexibility","volume":"32","author":"Xi","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"822","DOI":"10.7326\/M20-4648","article-title":"Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated, U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline","volume":"173","author":"Arnold","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e001404","DOI":"10.1136\/bmjgast-2024-001404","article-title":"Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD","volume":"11","author":"Schreiner","year":"2024","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1136\/gutjnl-2024-333074","article-title":"Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease","volume":"73","author":"Zhou","year":"2024","journal-title":"Gut"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/MJT.0000000000000344","article-title":"Effects of Atorvastatin on Serum High-Sensitive C-Reactive Protein and Total Cholesterol Levels in Asian Patients With Atrial Fibrillation","volume":"24","author":"Wang","year":"2017","journal-title":"Am. J. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2337\/dc22-0714","article-title":"Sodium\u2013Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study","volume":"46","author":"Wintzell","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/MNH.0000000000000584","article-title":"Renal effects of SGLT2 inhibitors","volume":"29","author":"Nespoux","year":"2020","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled, phase 2a study","volume":"28","author":"Harrison","year":"2022","journal-title":"Nat. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Li, P., Chen, W., Chen, R., Zhang, H., Yu, Z., Yan, H., Du, B., and Yang, P. (2025). Long-term effects of SGLT2 inhibitors on arrhythmias: A systematic review and meta-analysis. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1558367"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e031269","DOI":"10.1161\/JAHA.123.031269","article-title":"Impact of Sodium-Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With Diabetes: A Propensity-Score Matching Study and Meta-Analysis","volume":"12","author":"Zhao","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00228-023-03586-1","article-title":"The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review","volume":"80","author":"Zachou","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"ref_117","unstructured":"Deaton, J.G., and Nappe, T.M. (2025). Warfarin Toxicity, StatPearls Publishing."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2478\/acph-2022-0034","article-title":"Direct oral anticoagulants (DOACs): From the laboratory point of view","volume":"72","author":"Goreta","year":"2022","journal-title":"Acta Pharm."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1210\/clinem\/dgae394","article-title":"Risk of Adverse Events in Anticoagulated Patients With Atrial Fibrillation and Nonalcoholic Fatty Liver Disease","volume":"110","author":"Bucci","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Costache, R.S., Dragomiric\u0103, A.S., Gheorghe, B.E., Balaban, V.D., Stanciu, S.M., Jinga, M., and Costache, D.O. (2023). Oral Anticoagulation in Patients with Chronic Liver Disease. Medicina, 59.","DOI":"10.3390\/medicina59020346"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jacc.2019.04.061","article-title":"Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease","volume":"74","author":"Qamar","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e13397","DOI":"10.1111\/eci.13397","article-title":"Direct oral anticoagulants and advanced liver disease: A systematic review and meta-analysis","volume":"51","author":"Menichelli","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1055\/s-0043-1770100","article-title":"Risk of Bleeding in Liver Cirrhosis Receiving Direct Oral Anticoagulants: A Systematic Review and Meta-analysis","volume":"123","author":"Li","year":"2023","journal-title":"Thromb. Haemost."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/14656566.2024.2374463","article-title":"Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: Where are we today?","volume":"25","author":"Puengel","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_125","first-page":"86","article-title":"Fatty liver and drugs: The two sides of the same coin","volume":"21","author":"Miele","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Pascual, E., Rienda, I., Perez-Rojas, J., Rapisarda, A., Garcia-Llorens, G., Jover, R., and Castell, J.V. (2024). Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25105203"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1080\/21623945.2021.1983241","article-title":"Verapamil induces autophagy to improve liver regeneration in non-alcoholic fatty liver mice","volume":"10","author":"Lai","year":"2021","journal-title":"Adipocyte"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/bcp.12935","article-title":"Defining \u2018nutraceuticals\u2019: Neither nutritious nor pharmaceutical","volume":"83","author":"Aronson","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Chandra, S., Saklani, S., Kumar, P., Kim, B., and Coutinho, H.D.M. (2022). Nutraceuticals: Pharmacologically Active Potent Dietary Supplements. BioMed Res. Int., 2022.","DOI":"10.1155\/2022\/2051017"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Yue, H., Zhao, X., Liang, W., Qin, X., Bian, L., He, K., and Wu, Z. (2022). Curcumin, novel application in reversing myocardial fibrosis in the treatment for atrial fibrillation from the perspective of transcriptomics in rat model. Biomed. Pharmacother., 146.","DOI":"10.1016\/j.biopha.2021.112522"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1080\/15384101.2021.1932029","article-title":"Quercetin prevents isoprenaline-induced myocardial fibrosis by promoting autophagy via regulating miR-223-3p\/FOXO","volume":"20","author":"Hu","year":"2021","journal-title":"Cell Cycle"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Sokal-Dembowska, A., Jarmakiewicz-Czaja, S., Ferenc, K., and Filip, R. (2024). Can Nutraceuticals Support the Treatment of MASLD\/MASH, and thus Affect the Process of Liver Fibrosis?. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25105238"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Vrentzos, E., Pavlidis, G., Korakas, E., Kountouri, A., Pliouta, L., Dimitriadis, G.D., and Lambadiari, V. (2025). Nutraceutical Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Path to Liver Health. Nutrients, 17.","DOI":"10.3390\/nu17101657"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mam.2018.03.001","article-title":"Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action","volume":"64","author":"Scorletti","year":"2018","journal-title":"Mol. Asp. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/hep4.1906","article-title":"Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD","volume":"6","author":"Kosek","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clnu.2015.05.001","article-title":"Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial","volume":"35","author":"Nogueira","year":"2016","journal-title":"Clin. Nutr."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.amjcard.2014.10.022","article-title":"Effect of Omega-Three Polyunsaturated Fatty Acids on Inflammation, Oxidative Stress, and Recurrence of Atrial Fibrillation","volume":"115","author":"Vanderbilt","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2012.11.021","article-title":"Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation","volume":"61","author":"Macchia","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurjhf\/hft103","article-title":"n -3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: The GISSI-HF trial","volume":"15","author":"Aleksova","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4081\/monaldi.2011.196","article-title":"N-3 polyunsaturated fatty acids reduces post-operative atrial fibrillation incidence in patients undergoing \u201con-pump\u201d coronary artery bypass graft surgery","volume":"76","author":"Sorice","year":"2015","journal-title":"Monaldi Arch. Chest Dis."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1055\/s-0034-1367437","article-title":"Omega-3 Polyunsaturated Fatty Acids Reduce the Incidence of Postoperative Atrial Fibrillation in Patients with History of Prior Myocardial Infarction Undergoing Isolated Coronary Artery Bypass Grafting","volume":"62","author":"Wilbring","year":"2014","journal-title":"Thorac. Cardiovasc. Surg."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3904\/kjim.2015.30.5.571","article-title":"Evidence for beneficial effects of vitamin E","volume":"30","author":"Niki","year":"2015","journal-title":"Korean J. Intern. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.freeradbiomed.2024.05.027","article-title":"Vitamin E nomenclature. Is RRR-\u03b1-tocopherol the only vitamin E?","volume":"221","author":"Noguchi","year":"2024","journal-title":"Free Radic. Biol. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"101939","DOI":"10.1016\/j.xcrm.2025.101939","article-title":"Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study","volume":"6","author":"Song","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Al-Baiaty, F.D.R., Ishak, S., Mohd Zaki, F., Masra, F., Abdul Aziz, D.A., Wan Md Zin, W.N., Yee Hing, E., Kuthubul Zaman, A.S., Abdul Wahab, N., and Muhammad Nawawi, K.N. (2024). Assessing the efficacy of tocotrienol-rich fraction vitamin E in obese children with non-alcoholic fatty liver disease: A single-blind, randomized clinical trial. BMC Pediatr., 24.","DOI":"10.1186\/s12887-024-04993-8"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.jacc.2013.07.014","article-title":"A Randomized Controlled Trial to Prevent Post-Operative Atrial Fibrillation by Antioxidant Reinforcement","volume":"62","author":"Rodrigo","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/icvts\/ivs154","article-title":"Ageing improves the antioxidant response against postoperative atrial fibrillation: A randomized controlled trial","volume":"15","author":"Rodrigo","year":"2012","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Yaikwawong, M., Jansarikit, L., Jirawatnotai, S., and Chuengsamarn, S. (2025). Curcumin for Inflammation Control in Individuals with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial. Nutrients, 17.","DOI":"10.3390\/nu17121972"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.clnesp.2024.05.003","article-title":"Evaluation of the effectiveness of curcumin and piperine co-supplementation on inflammatory factors, cardiac biomarkers, atrial fibrillation, and clinical outcomes after coronary artery bypass graft surgery","volume":"62","author":"Tehrani","year":"2024","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e70108","DOI":"10.1111\/acel.70108","article-title":"Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients","volume":"24","author":"Mury","year":"2025","journal-title":"Aging Cell"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ajcnut.2024.07.013","article-title":"Quercetin intervention reduced hepatic fat deposition in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled crossover clinical trial","volume":"120","author":"Li","year":"2024","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Ali Sangouni, A., Abdollahi, S., and Mozaffari-Khosravi, H. (2022). Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: A double-blind, randomized controlled trial. BMC Cardiovasc. Disord., 22.","DOI":"10.1186\/s12872-022-02637-2"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1017\/S0007114515002433","article-title":"The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: A randomised, double-blind, placebo-controlled study","volume":"114","author":"Faghihzadeh","year":"2015","journal-title":"Br. J. Nutr."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1024\/0300-9831\/a000528","article-title":"No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease","volume":"90","author":"Farzin","year":"2020","journal-title":"Int. J. Vitam. Nutr. Res."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/11\/1713\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:43:21Z","timestamp":1762350201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/11\/1713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":154,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["life15111713"],"URL":"https:\/\/doi.org\/10.3390\/life15111713","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]}}}